Navigation Links
VIA Pharmaceuticals' Lead Compound, VIA-2291, Chosen as a Top Ten Most Licensable Cardiovascular Program for Windhover Information's Therapeutic Area Partnerships Conference
Date:10/19/2007

since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond VIA's control and which could materially affect actual results, levels of activity, performance or achievements.

Factors that may cause actual results to differ materially from current expectations include, but are not limited to:

* our ability to obtain necessary financing;

* our ability to control our operating expenses;

* our ability to recruit and enroll patients for the CEA, ACS and FDG-PET

clinical trials;

* our ability to successfully complete our clinical trials of VIA-2291 on

expected timetables and the outcomes of such clinical trials;

* the results of our clinical trials, including without limitation, with

respect to the safety and efficacy of VIA-2291;

* the outcome of any legal proceedings;

* our ability to obtain necessary FDA approvals;

* our ability to successfully commercialize VIA-2291;

* our ability to obtain and protect our intellectual property related to

our product candidates;

* our potential for future growth and the development of our product

pipeline;

* our ability to form and maintain collaborative relationships to develop

and commercialize our product candidates;

* general economic and business conditions; and

* the other risks described under the heading "Risk Factors" in our

Quarterly Report on Form 10-Q for the quarter ended June 30, 2007 on

file with the SEC and in our Form S3 Amendment No. 3 filed with the SEC

October 15, 2007.

All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements set forth above. Forward-looking statements speak only as of the date they are made, and VIA undertakes no obligation to update publicly any of these statements in light o
'/>"/>

SOURCE VIA Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

4

GOOD

Page: 1 2 3 4

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Quintessence cancer treatment chosen for clinical studies
4. Evansville site chosen for biodiesel plant
5. Fiservs Banklink chosen by Union Bank of California
6. Detection of mRNAs on Cryosections of the Cardiovascular System Using DIG-Labeled RNA Probes
7. Multiplexed Quantitative Peptide Assays for Protein Biomarkers of Cardiovascular Disease in Human Plasma
8. NY Medical Center Selects Camtronics for Cardiovascular Image and Information Management
9. 7 Programming
10. 7 Programming
11. 7 Programming
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Mississauga, Ontario (PRWEB) May 21, 2013 ... expert scientists of the ITN to design the ... usefulness of two key clinical models used in ... Chamber (EEC) and Nasal Allergen Challenge (NAC) models. ... supported by numerous publications, to date no direct ...
(Date:5/21/2013)... May 21, 2013 PathoGenetix, Inc., a ... strain typing, announced today that it has successfully identified ... coli strains obtained from the Centers for Disease Control ... (GSS™) technology. The findings are detailed in a ... American Society for Microbiology in Denver on Monday. , ...
(Date:5/20/2013)... Al Khaimah, UAE (PRWEB) May 21, 2013 ... private equity consultancy specializing in “game-changing” life science and ... of Ms. Dalia Dergham to its International Project Team. ... to bring even greater multi-cultural depth to Grace Century ... projects around the globe. , Ms. Dergham holds both ...
(Date:5/20/2013)... May 20, 2013  (PSHR) Pacific Shore Holdings, ... products across a broad range of product categories ... investor relations firm, BlueWater Advisory Group, to provide ... trading process, and to direct the company,s outreach ... Matthew Mills , Pacific ...
Breaking Biology Technology:Inflamax Research selected by the Immune Tolerance Network and the National Institutes of Health to conduct a landmark clinical study on the underlying mechanisms of allergic inflammation. 2New Genotyping System Identifies Pathogenic E. coli Outbreak Strains 2New Genotyping System Identifies Pathogenic E. coli Outbreak Strains 3Dalia Dergham Joins Grace Century FZ LLC International Project Team 2Pacific Shore Holdings Retains Investor Relations Firm 2
... 11 /Xinhua-PRNewswire-FirstCall/ -- BMP,Sunstone Corporation (Nasdaq: BJGP ... due to the technical difficulties encountered on,today,s conference ... tomorrow,Wednesday, November 12, 2008. On this call, BMP ... since technical difficulties prevented the,Company from addressing all ...
... Rapid Detection Flu A+B Test Differentiates Flu Strains A ... 20 percent of the U.S. population becomes ill with ... bacterial infections,present similarly to influenza. Because of this, overuse ... to the growing problem of,antibiotic resistance., This flu ...
... Contamination by an unknown,organism often calls for ... organism can be identified and eliminated. Such ... and productivity of medical device,and pharmaceutical manufacturers ... Microbial ID Breakthrough: How DNA Sequencing,Services Help ...
Cached Biology Technology:BMP Sunstone to Host Follow-Up 3Q08 Conference Call Due to Technical Difficulties Encountered on Tuesday's Call 2BMP Sunstone to Host Follow-Up 3Q08 Conference Call Due to Technical Difficulties Encountered on Tuesday's Call 3MultiVu Video Feed: New Rapid Test to Diagnose Flu May Help With Upcoming Flu Season 2White Paper Details How DNA Sequencing Services Can Prevent Cleanroom Shutdowns at Medical Device and Pharmaceutical Manufacturers 2White Paper Details How DNA Sequencing Services Can Prevent Cleanroom Shutdowns at Medical Device and Pharmaceutical Manufacturers 3
(Date:5/21/2013)... , May 21, 2013 Royal Philips Electronics ... the world,s first portable ultrasound with Philips, industry leading ... capability. The CX50 xMATRIX with available Live 3D TEE ... at the EuroPCR, official meeting for the ... Since its launch in 2012, Philips CX50 ...
(Date:5/21/2013)... alter the way genes function without changing the ... the blood of pregnant women during any trimester, ... in the weeks after giving birth, and an ... The findings of the small study involving 52 ... Molecular Psychiatry . , "Postpartum depression can ...
(Date:5/20/2013)... Bacteria resistant to the antibiotic colistin are also ... human body, according to a study in ... American Society for Microbiology. Cross-resistance to colistin and ... the body against bacterial attack, could mean that ... saddled with a crippled immune response. Colistin is ...
Breaking Biology News(10 mins):Philips CX50 xMATRIX now offers world-class interventional and diagnostic features on single portable system 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 3Resistance to last-line antibiotic makes bacteria resistant to immune system 2Resistance to last-line antibiotic makes bacteria resistant to immune system 3
... have recovered fossils of a 60-million-year-old South American snake whose ... seem a bit cuter and more cuddly. Named ... snake,s vertebrae suggest it weighed 1140 kg (2,500 pounds) and ... report describing the find appears in this week,s Nature ...
... University of Michigan scientists report highly encouraging evidence that ... other microbes, may be able to quell the ravaging, ... deaths. Cystic fibrosis is an inherited chronic ... the United States. Patients have mucus-clogged lungs that leave ...
... TALLAHASSEE, Fla. -- The facial structure of an ancient ... them to eat large, hard nuts and seeds as ... study by an international team of researchers that includes ... published in the journal Proceedings of the National ...
Cached Biology News:Largest prehistoric snake on record discovered in Colombia 2Largest prehistoric snake on record discovered in Colombia 3Nanoemulsion potent against superbugs that kill cystic fibrosis patients 2Nanoemulsion potent against superbugs that kill cystic fibrosis patients 3
...
... The product contains 5 ml of DETACHaBEAD ... release mouse CD4+ T cells from Dynabeads ... mosue CD4+ T cells from Dynabeads Mouse ... cells are suitable for any downstream application ...
RECOMBINANT EQUINE IL-4 Product Type: Recombinant Protein...
Porcine IFN-gamma ELISpot Development Module...
Biology Products: